US approves first blood test for Alzheimer's
The United States on 16 May 2025 approved the first blood test for Alzheimer's, a move that could help patients begin treatment earlier with newly approved drugs that slow the progression of the devastating neurological disease.
How does the test work
The test, developed by Fujirebio Diagnostics, measures the ratio of two proteins in the blood. The ratio is correlated with amyloid plaques in the brain -- a hallmark of Alzheimer's that, until now, has been detected only through brain scans or spinal fluid analysis. "Alzheimer's disease impacts too many people -- more than breast cancer and prostate cancer combined," said Marty Makary, Food and Drug Administration Commissioner.
"Knowing that 10 percent of people aged 65 and older have Alzheimer's, and that by 2050 that number is expected to double, I am hopeful that new medical products such as this one will help patients."
There are currently two FDA approved treatments for Alzheimer's: lecanemab and donanemab, which target amyloid plaque and have been shown to modestly slow cognitive decline, though they do not cure the disease.
Advocates for the intravenous antibody therapies, including many neurologists, say they can offer patients a few additional months of independence -- and are likely to be more effective if started earlier in the disease's course.
Results and future possibilities
In clinical studies, the blood test produced results largely in line with positron emission tomography (PET) brain scans and spinal fluid analysis. "Today's clearance is an important step for Alzheimer's diagnosis, making it easier and potentially more accessible for US patients earlier in the disease," said Michelle Tarver of the FDA's Center for Devices and Radiological Health.
The test is authorised for use in clinical settings for patients showing signs of cognitive decline, and results must be interpreted alongside other clinical information. Alzheimer's is the most common form of dementia. It worsens over time, gradually robbing people of their memories and independence.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Amid staff crunch, FDA to appoint 40 food safety officers this week
Mumbai: After operating with just five food safety officers (FSOs) for nearly a year, the city's Food and Drug Administration (FDA) is expected to appoint at least 40 new FSOs by June 7, in a bid to address a severe staffing shortfall. The drug department under the FDA is similarly stretched thin with only five field officers in the city. It may take another year to reach its required strength of 25 to 30 here. Officials say the shortage significantly hampered inspections and enforcement, overburdening the limited staff. Following action taken against a Zepto facility in Dharavi on Sunday, FDA officials admitted they currently lack the manpower to inspect similar warehouses operated by delivery platforms. "Food safety officers are the field workers who conduct sampling and routine inspections. Without adequate numbers, essential tasks like testing for milk adulteration or checking ice quality can't happen at the large scale required," said Mangesh Mane, joint commissioner (Food). Although over 40 officers are expected to be appointed within days, Mane said training will take another month or two. "We expect them to join the workforce by October," he added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Switch to UnionBank Rewards Card UnionBank Credit Card Apply Now Undo FDA commissioner Rajesh Narvekar said the food division has 350 sanctioned posts, but only 132 are filled, leaving a gap of 218 officers. After repeated proposals to the govt and the Maharashtra Public Service Commission, 194 food safety officers and 8 assistant commissioners were finally selected, bringing the department's total strength to just over 300. However, according to food safety norms, one officer per 1,000 food business operators, the FDA needs at least 1,100 officers. The drug department, meanwhile, has 200 sanctioned posts but only 48 filled, with 152 vacancies still open. A revised recruitment proposal has been submitted to MPSC, but officials say it will take another year. The persistent shortfall is largely due to a prolonged pause in recruitment drives and a wave of retirements, promotions, and transfers over the past year or more. "We are meeting our targets by working extra hours. Leaves are being sacrificed, but we're trying not to let it affect our functioning," said an official from the drug department. Still, gaps remain. "There's no major problem due to shortfall in issuing manufacturing licenses after conducting their inspections," said Narvekar. "The problem is in monitoring retailers and wholesalers," he added. Abhay Pandey, president of the All Food and Drug Licence Holders Foundation, warned of serious public health consequences. "Random sampling at retail stores and distributor levels simply isn't happening for more than a year at a scale it should. Without it, there's no way to ensure quality control," he said.
Time of India
5 hours ago
- Time of India
Entrepreneur finds alternative to make areca plates safer after US ban
Mangaluru: Entrepreneur and researcher Nivedan Nempe has developed an innovative, eco-friendly alternative following the recent US ban on arecanut leaf sheath dinnerware. His intervention comes at a crucial time, as areca growers and industry experts from Karnataka's areca belt have appealed to Prime Minister Narendra Modi to seek the lifting of the restriction. The US Food and Drug Administration (FDA) issued an import alert banning dinnerware made from areca catechu sheaths, citing the presence of naturally occurring toxins that may migrate into food at unsafe levels. The FDA's concerns significantly impacted India's $400-500 million areca plate industry, with nearly 80–85% of exports directed to the US. Most manufacturers are concentrated in Dakshina Kannada and Shivamogga, and the ban threatens the livelihoods of many families. Nivedan, founder of Areca Tea and operating in Udupi and Shivamogga, acknowledged the FDA's concerns and told TOI: "As a preventive step, the FDA banned imports. But this severely affects Indian manufacturers. The Indian industry made efforts, including writing to the FDA, but the industry is at risk." In response, Nempe engineered a food-grade, anti-microbial paper lining that acts as a barrier between the food and the areca plate, preventing toxin migration and fungal growth. "The material is certified, heat-resistant up to 300°C, durable, printable, and gives a premium finish. It meets international safety standards without altering the existing production process," he said. While the innovation may increase production costs by 10–15%, Nivedan believes that it is the best way forward. "Our lab results were positive on all parameters. It even looks better than bagasse plates. My goal is to safeguard the industry and support the farmers by supplying this new food-grade paper."
&w=3840&q=100)
First Post
11 hours ago
- First Post
US okays Moderna's 'next generation' Covid-19 vaccine
The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose, a fifth of the dose of its current COVID-19 vaccine, Spikevax (mRNA-1273) by refining its immune target read more Moderna logo is seen displayed in this illustration taken, May 3, 2022. REUTERS Moderna, a vaccine manufacturer, said late last week that the FDA has authorised its next-generation COVID-19 vaccine. The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose, a fifth of the dose of its current COVID-19 vaccine, Spikevax (mRNA-1273) by refining its immune target. Moderna's approval was based on a phase 3 randomised controlled trial involving 11,400 participants ages 12 and older. The trial found that a 10-microgram (μg) dose of mNexspike demonstrated a 9.3% higher relative vaccine efficacy (rVE) compared to a 50-μg dose of Spikevax, with a 13.5% higher rVE in adults ages 65 and older. The two vaccinations have identical safety profiles, according to the manufacturer. STORY CONTINUES BELOW THIS AD The approval 'adds an important new tool to help protect people at high risk of severe disease from COVID-19,' Stephane Bancel, Moderna's CEO, said in a statement Saturday. The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus. That's the same limit that the FDA set in licensing another COVID-19 vaccine option from competitor Novavax. Those restrictions are a departure from how the US has handled COVID-19 vaccines until now, reflecting scepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials. Moderna's existing vaccine doesn't face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall. The news came just days after the Trump administration cancelled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results. STORY CONTINUES BELOW THIS AD
